The role of glucocorticoid action in the pathophysiology of the Metabolic Syndrome

被引：219

作者：

Wang M. ^{[1
]}

机构：

[1] Department of Metabolic Disorders, Amgen Inc., Thousand Oaks, CA

来源：

Nutrition & Metabolism | / 2卷 / 1期

关键词：

Insulin Resistance; Cortisol; Metabolic Syndrome; Corticosterone; Carbenoxolone;

D O I：

10.1186/1743-7075-2-3

中图分类号：

学科分类号：

摘要：

Glucocorticoids are stress hormones that modulate a large number of physiological actions involved in metabolic, inflammatory, cardiovascular and behavioral processes. The molecular mechanisms and the physiological effects of glucocorticoids have been extensively studied. However, the involvement of glucocorticoid action in the etiology of the Metabolic Syndrome has not been well appreciated. Recently, accumulating clinical evidence and animal genetics studies have attracted growing interest in the role of glucocorticoid action in obesity and insulin resistance. This review will discuss the metabolic effects in the context of glucocorticoid metabolism and establish the association of glucocorticoid action with the features of the Metabolic Syndrome, especially obesity and insulin resistance. Special discussions will be focused on corticosteroid-binding globulin and 11β-hydroxysteroid dehydrogenase type 1, two proteins that mediate glucocorticoid action and have been implicated in the Metabolic Syndrome. Due to the complexities of the glucocorticoid biology and the Metabolic Syndrome and limited space, this review is only intended to provide a general link between the two areas with broad rather than in-depth discussions of clinical, pharmacological and genetic findings. © 2005 Wang; licensee BioMed Central Ltd.

引用

共 148 条

[111] Lloyd-MacGilp S.A., Nelson S.M., Florin M., Lo M., McKinnell J., Sassard J., Kenyon C.J., 11β-hydroxysteroid dehydrogenase and corticosteroid action in lyon hypertensive rats, Hypertension, 34, 5, pp. 1123-1128, (1999)
[112] Brem A.S., Bina R.B., King T.C., Morris D.J., Localization of 2 11β-OH steroid dehydrogenase isoforms in aortic endothelial cells, Hypertension, 31, 1 PART 2, pp. 459-462, (1998)
[113] Brem A.S., Bina R.B., Hill N., Alia C., Morris D.J., Effects of licorice derivatives on vascular smooth muscle function, Life Sci, 60, 3, pp. 207-214, (1997)
[114] Walker B.R., Sang K.S., Williams B.C., Edwards C.R., Direct and indirect effects of carbenoxolone on responses to glucocorticoids and noradrenaline in rat aorta, J Hypertens, 12, 1, pp. 33-39, (1994)
[115] Kuhn R.W., Green A.L., Raymoure W.J., Siiteri P.K., Immunocytochemical localization of corticosteroid-binding globulin in rat tissues, J Endocrinol, 108, 1, pp. 31-36, (1986)
[116] Werthamer S., Samuels A.J., Amaral L., Identification and partial purification of "transcortin"-like protein within human lymphocytes, J Biol Chem, 248, 18, pp. 6398-6407, (1973)
[117] Fernandez-Real J.M., Pugeat M., Grasa M., Broch M., Vendrell J., Brun J., Ricart W., Serum corticosteroid-binding globulin concentration and insulin resistance syndrome: A population study, J Clin Endocrinol Metab, 87, 10, pp. 4686-4690, (2002)
[118] Ousova O., Guyonnet-Duperat V., Iannuccelli N., Bidanel J.P., Milan D., Genet C., Llamas B., Yerle M., Gellin J., Chardon P., Emptoz-Bonneton A., Pugeat M., Mormede P., Moisan M.P., Corticosteroid binding globulin: A new target for cortisol-driven obesity, Mol Endocrinol, 18, 7, pp. 1687-1696, (2004)
[119] Torpy D.J., Bachmann A.W., Grice J.E., Fitzgerald S.P., Phillips P.J., Whitworth J.A., Jackson R.V., Familial corticosteroid-binding globulin deficiency due to a novel null mutation: Association with fatigue and relative hypotension, J Clin Endocrinol Metab, 86, 8, pp. 3692-3700, (2001)
[120] Emptoz-Bonneton A., Cousin P., Seguchi K., Avvakumov G.V., Bully C., Hammond G.L., Pugeat M., Novel human corticosteroid-binding globulin variant with low cortisol-binding affinity, J Clin Endocrinol Metab, 85, 1, pp. 361-367, (2000)

← 6 7 8 9 10 11 12 13 14 15 →